Primary hyperaldosteronism
(Conn syndrome)

Primary hyperaldosteronism is an endocrine cause of sustained arterial hypertension resulting from excessive and relatively autonomous secretion of aldosterone by the adrenal cortex, with consequent suppression of renin and disruption of fluid and electrolyte homeostasis. Physiologically, aldosterone is the hormone that regulates sodium and potassium balance through activation of the mineralocorticoid receptor and contributes to the control of extracellular fluid volume. In primary hyperaldosteronism, this system loses its dependence on the body's physiological requirements and imposes an inappropriate, chronic signal capable of altering blood pressure regulation and remodeling the kidneys, heart and blood vessels.

Its clinical significance derives from the fact that aldosterone excess does not merely increase blood pressure, but also exerts direct pro-inflammatory and profibrotic effects on the myocardium, vascular wall and renal parenchyma. This increases the risk of atrial fibrillation, heart failure, stroke, nephropathy and albuminuria compared with essential hypertension of comparable severity. The condition may present with overt hypokalemia, but potassium levels are very often normal. Recognition therefore depends on structured clinical suspicion and a diagnostic pathway that first identifies the condition and then determines whether aldosterone production is unilateral or bilateral, because this distinction determines the most effective treatment.

The epidemiological understanding of primary hyperaldosteronism has changed radically from the historical view of a rare disorder invariably associated with hypokalemia. It is now recognized as one of the most common causes of secondary hypertension and, above all, as a modifiable cause of mineralocorticoid receptor-mediated target-organ damage. Estimated prevalence varies according to the clinical setting and selection criteria. It is lower in unselected populations with hypertension, but increases progressively in high-risk settings such as resistant hypertension, severe hypertension and hypertension associated with hypokalemia. This variability is not merely a statistical detail, but reflects the broad biological spectrum of the condition, ranging from clearly autonomous forms with elevated aldosterone and suppressed renin to subtler phenotypes in which mineralocorticoid signaling remains inappropriate in relation to sodium status.

Underdiagnosis is a central epidemiological issue. Most patients who are subsequently found to have primary hyperaldosteronism are initially treated as having essential hypertension, because normal potassium levels reduce clinical suspicion and because assessment of the aldosterone-renin pair requires pre-analytical and interpretative conditions that are not always respected in routine practice. This has practical consequences: prolonged exposure to aldosterone excess, even when blood pressure is considered acceptably controlled, maintains the mechanisms responsible for cardiovascular and renal remodeling.

Clinical risk factors that increase the pre-test probability include resistant hypertension or hypertension requiring multiple medications, hypertension with spontaneous or diuretic-induced hypokalemia, obstructive sleep apnea, an associated adrenal incidentaloma, and a suggestive family history, such as early-onset hypertension or cerebrovascular events at a relatively young age. In these settings, the probability that primary hyperaldosteronism is the underlying cause is sufficiently high to make screening a high-yield diagnostic and prognostic strategy.

Age and sex influence the phenotype more than the mere presence of the disorder. In younger individuals, a clinically meaningful proportion of cases may be related to familial forms or aldosterone-producing adenomas with a more overt clinical profile. In adults and older people, bilateral forms and presentations dominated by cardiovascular complications, such as atrial fibrillation or heart failure, become more common, sometimes without hypokalemia. This age-related transition contributes to diagnostic delays precisely among patients in whom targeted treatment may have the greatest prognostic impact.

Another epidemiological factor is the relationship with the metabolic profile. Primary hyperaldosteronism is more frequently associated with abnormalities of glucose metabolism and an increased risk of diabetes than comparable essential hypertension, a finding consistent with the systemic effects of mineralocorticoid activation on inflammation, oxidative stress and endothelial function. This does not mean that primary hyperaldosteronism is a metabolic disorder in the strict sense, but it reinforces the concept of a systemic condition in which a single chronic hormonal signal amplifies cardiovascular and renal vulnerability.

Individual vulnerability also depends on target-organ reserve. Chronic kidney disease, structural heart disease, previous arrhythmias, frailty in older people and polypharmacy amplify the consequences of aldosterone excess and influence treatment selection and follow-up. These factors increase the risk both of disease-related complications and of treatment-related adverse effects, particularly hyperkalemia during therapy with mineralocorticoid receptor antagonists.

Primary hyperaldosteronism results from excessive aldosterone production that is inappropriate in relation to sodium status and regulation of the renin-angiotensin system. Under physiological conditions, the adrenal zona glomerulosa primarily integrates signals mediated by angiotensin II and potassium, with a transient contribution from adrenocorticotropic hormone (ACTH), and regulates expression of the key enzyme aldosterone synthase (CYP11B2). The purpose of this regulatory circuit is to preserve perfusion and electrolyte homeostasis. When sodium availability is high and intravascular volume is expanded, renin is suppressed, angiotensin II decreases and aldosterone secretion falls. In primary hyperaldosteronism, this coupling is disrupted: aldosterone remains elevated or relatively inappropriate, while renin remains suppressed.

From an etiological perspective, the most common forms include unilateral production, typically caused by an aldosterone-producing adenoma, and bilateral production, often described as bilateral zona glomerulosa hyperplasia. These are accompanied by rarer but clinically important forms, including familial primary hyperaldosteronism and conditions in which micronodules or aldosterone-producing cell clusters contribute to partial autonomy that may overlap with the spectrum of low-renin hypertension. In clinical practice, the decisive question is not only whether aldosterone excess is present, but whether it originates from one gland or both, because this distinction separates a condition potentially curable by adrenalectomy from one requiring chronic medical therapy directed at the mineralocorticoid receptor.

Modern understanding of pathogenesis has identified a series of somatic mutations in adenomas that converge on a common physiological pathway: increased intracellular calcium in zona glomerulosa cells, which stimulates CYP11B2 expression and aldosterone steroidogenesis. Mutations affecting ion channels or pumps, including those that alter potassium permeability or membrane depolarization, promote sustained calcium entry and therefore autonomous secretion. This explains why an adenoma is not merely a mass that produces aldosterone, but tissue in which electrical signaling and calcium regulation have been reprogrammed toward aldosterone production.

The pathogenetic basis varies among familial forms. Some are associated with aldosterone production that becomes partly dependent on nonphysiological signals, such as abnormal ACTH regulation in specific genetic settings, while others result from germline mutations that reproduce constitutionally mechanisms similar to those observed in adenomas. These conditions are important because they alter treatment strategy in a minority of patients and, when suspected, direct clinicians toward a dedicated diagnostic pathway, particularly in cases of early onset or strong familial clustering.

The pathophysiology of primary hyperaldosteronism originates from the action of aldosterone on the mineralocorticoid receptor in the distal nephron. Receptor activation increases the expression and activity of sodium channels and transporters, promoting sodium and water reabsorption and causing expansion of extracellular fluid volume. At the same time, secretion of potassium and hydrogen ions increases, predisposing to hypokalemia and metabolic alkalosis, especially when sodium intake is high or diuretics are being used. Volume expansion suppresses renin, making the aldosterone-renin pair a characteristic biochemical signature of the condition.

Beyond the kidney, aldosterone exerts direct effects on the heart and blood vessels. Mineralocorticoid receptor activation in the myocardium and vascular wall promotes fibrosis, endothelial dysfunction, oxidative stress and vascular remodeling, increasing arterial stiffness and susceptibility to arrhythmias, particularly through atrial remodeling and electrolyte disturbances. These effects explain why primary hyperaldosteronism is associated with a higher frequency of atrial fibrillation, stroke and heart failure than essential hypertension at comparable blood pressure levels. Hypokalemia, when present, further increases cardiac electrical vulnerability, but it is not required for risk to rise, because a substantial proportion of damage is mediated by chronic mineralocorticoid receptor signaling.

At renal level, aldosterone excess may initially cause hyperfiltration, accompanied by albuminuria and progressive glomerular injury. The apparently preserved renal function observed in some patients may worsen after specific treatment, not because treatment damages the kidney, but because it corrects hyperfiltration and reveals the patient's true renal reserve. This point is essential when interpreting follow-up findings. A reduction in estimated glomerular filtration rate after correction of aldosterone excess may represent hemodynamic normalization rather than disease progression, especially when accompanied by reduced albuminuria and improved blood pressure control.

The clinical picture of primary hyperaldosteronism is dominated by hypertension, but presentation is heterogeneous because it depends on the duration of aldosterone exposure, sodium intake, cardiovascular and renal reserve, and the degree of potassium disturbance. Many patients report no specific symptoms, and the condition emerges as difficult-to-control hypertension or as a laboratory finding of suppressed renin. In other cases, particularly when hypokalemia is marked, the clinical picture is more suggestive and leads earlier to consideration of an endocrine cause.

During the medical history, hypertension may be described as severe, early in onset or resistant to multiple medications. The patient may report headache, easy fatigability and reduced exercise tolerance, but these symptoms are common to many forms of hypertension and have no independent discriminatory value. When hypokalemia is present, muscle cramps, weakness, paresthesia, polyuria and polydipsia may occur because potassium deficiency impairs neuromuscular excitability and urinary concentrating ability. In some situations, the clinical history includes episodes of hypokalemia discovered during diuretic therapy or clinical deterioration. This pattern should be considered a warning sign rather than an unavoidable adverse effect.

Primary hyperaldosteronism may initially present with cardiovascular events. Palpitations and a diagnosis of atrial fibrillation may be the first evident finding, especially in patients who do not consider themselves symptomatic. Heart failure, stroke or ischemic heart disease may also provide the context in which the condition becomes apparent, after previous hypertension and mineralocorticoid activation have promoted remodeling and electrical instability. In these cases, identifying primary hyperaldosteronism has significance beyond blood pressure control because it enables targeted treatment that reduces the risk of recurrence and progression of target-organ damage.

On physical examination, findings are generally those of hypertension and its complications, including elevated blood pressure, signs of left ventricular hypertrophy or heart failure in advanced cases, and occasionally signs of potassium depletion such as proximal muscle weakness. However, physical examination often provides no pathognomonic findings. Clinical assessment must therefore focus on recognizing risk patterns and rationally integrating the medical history, current treatment and biochemical data. Careful reconstruction of the medication history is particularly important because diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and other treatments influence renin and aldosterone and may mask or mimic abnormal hormonal profiles.

Another frequent clinical feature is the coexistence of obstructive sleep apnea and resistant hypertension. In these patients, blood pressure is often elevated at night and blood pressure variability is greater. Primary hyperaldosteronism may contribute through sodium retention as well as through effects on vascular stiffness and sympathetic tone. The presence of an adrenal incidentaloma in a patient with hypertension should also prompt targeted assessment, because an aldosterone-producing adenoma may be morphologically indistinguishable from a nonfunctioning adenoma and evaluation must therefore be functional rather than exclusively radiological.

Overall, the clinical presentation of primary hyperaldosteronism is often silent in terms of specific symptoms but conspicuous in terms of its consequences. The clinical assessment should therefore begin with hypertension, identify signs of mineralocorticoid autonomy and progress toward causal or pathophysiological treatment, rather than merely adding antihypertensive medications without correcting the underlying mechanism.

Primary hyperaldosteronism should be systematically suspected in all settings in which the pre-test probability is high and identification would substantially alter prognosis and treatment strategy. The classic indication is resistant hypertension, defined as blood pressure that remains uncontrolled despite treatment with multiple medications at adequate doses. In this setting, the prevalence of the condition is particularly high and the benefit of targeted treatment is substantial. Severe or early-onset hypertension, especially when associated with a suggestive family history, is also an appropriate setting for screening.

The association between hypertension and hypokalemia is a strong indicator, but it should not be interpreted rigidly. Potassium may remain normal for a long time, and hypokalemia may be precipitated by diuretics or changes in sodium intake. Diuretic-induced or recurrent hypokalemia in a patient with hypertension should therefore strengthen clinical suspicion. When muscle weakness, cramps or polyuria occur together with hypokalemia, the probability that aldosterone excess is clinically relevant increases further.

Another setting with high diagnostic value is hypertension associated with an adrenal incidentaloma. In this context, assessment of aldosterone and renin forms part of the functional characterization of the lesion, because morphology compatible with an adenoma does not exclude hormonal activity and because surgical decisions cannot be based solely on size or radiological appearance. Similarly, obstructive sleep apnea associated with difficult-to-control hypertension represents a setting in which the probability of primary hyperaldosteronism is increased and in which correction of mineralocorticoid signaling may facilitate blood pressure control and reduce cardiovascular risk.

Suspicion should also be high when cardiovascular complications appear disproportionate to the apparent history of hypertension. A diagnosis of atrial fibrillation, marked left ventricular hypertrophy, albuminuria or declining renal function in a patient whose hypertension does not appear particularly severe should prompt consideration of aldosterone as an amplifier of target-organ damage, irrespective of office blood pressure measurements. In this sense, primary hyperaldosteronism is a condition in which biological severity does not always correspond to perceived clinical severity.

Finally, in cases of very early onset, a strong family history or severe hypertension affecting several family members, the possibility of familial forms should be incorporated into clinical reasoning. In these situations, suspicion extends beyond the diagnosis of primary hyperaldosteronism itself and includes the need for specialist assessment to define the phenotype and guide the most appropriate treatment, including prevention of events in other family members.

The diagnosis of primary hyperaldosteronism requires a multistep pathway: identification of a biochemical profile compatible with aldosterone excess and renin suppression, confirmation of autonomous secretion when necessary, and determination of the lateralization of production to establish whether treatment should be surgical or medical. The starting point is screening with the aldosterone-renin ratio, commonly referred to as the ARR. This test has high clinical utility but is sensitive to pre-analytical conditions and medications. Hypokalemia, sodium restriction, posture, time of blood sampling and antihypertensive treatments can alter renin and aldosterone and produce misleading results. Patient preparation and contextual interpretation are therefore integral components of diagnostic quality rather than secondary details.

In practice, screening is convincing when renin is suppressed and aldosterone is inappropriately elevated relative to that suppression. A high ARR with an aldosterone concentration that is not elevated does not establish the disorder, while elevated aldosterone with nonsuppressed renin suggests other conditions, including secondary hyperaldosteronism. Interpretation must also account for differences among laboratories in renin and aldosterone assays and measurement units. It is therefore preferable to assess physiological coherence and use locally validated cutoffs in experienced centers.

After a suggestive screening result, the next step is confirmation of autonomous secretion. International guidelines recommend suppression tests based on the principle that, in individuals without autonomous secretion, sodium loading or pharmacological modulation of the renin-angiotensin system reduces aldosterone production. Test selection depends on the clinical context, patient safety and local expertise, because some procedures require closer monitoring and careful potassium control.

Diagnostic pathway for primary hyperaldosteronism

• Screening: documentation of suppressed renin with inappropriate aldosterone concentrations and an increased aldosterone-renin ratio (ARR) under controlled pre-analytical conditions.
• Confirmation of autonomy: selected suppression testing based on safety and clinical context, with prior correction of hypokalemia and assessment of sodium intake.
• Etiological and morphological assessment: adrenal CT to characterize the glands and identify lesions, always integrating radiological findings with the functional profile.
• Subtyping: adrenal venous sampling (AVS) in candidates for surgical treatment to distinguish unilateral from bilateral production and guide therapeutic decisions.

The initial imaging investigation, after confirmation or when clinical and biochemical evidence is particularly strong, is generally adrenal CT. Its role is twofold: to define adrenal anatomy and identify lesions requiring attention because of their radiological characteristics, and to provide an anatomical map for planning possible adrenal venous sampling. However, CT cannot replace functional assessment. Nonfunctioning adenomas are common, particularly with increasing age, and a unilateral lesion does not necessarily indicate unilateral aldosterone production. This is the point at which radiological findings, when interpreted in isolation, may lead to inappropriate treatment decisions.

The decisive step for distinguishing unilateral from bilateral disease in patients who may benefit from adrenalectomy is AVS, which is regarded as the functional reference standard for lateralizing secretion. The procedure is technically demanding and requires expertise because it involves selective catheterization of the adrenal veins and interpretation of hormonal gradients according to selectivity and lateralization criteria. The value of AVS is greatest when the surgical decision would substantially alter the patient's natural history. Its indication should be discussed in relation to age, comorbidities, surgical risk and the realistic probability of clinical benefit.

Assessment of target-organ damage and complications is equally essential because it influences the urgency and objectives of treatment. An electrocardiogram (ECG) and, when indicated, echocardiography help quantify cardiac remodeling and arrhythmias. Renal assessment includes creatinine, estimated glomerular filtration rate and albuminuria, with the expectation that correction of aldosterone excess may alter filtration through normalization of hyperfiltration. Integrated management of these aspects is not separate from diagnosis, because it defines risk and priorities and makes the transition to surgery or mineralocorticoid receptor antagonist therapy safer.

The classification of primary hyperaldosteronism is clinically useful when it translates a diagnostic label into a treatment choice and risk estimate. The most important distinction is between unilateral and bilateral forms. Unilateral forms commonly include aldosterone-producing adenoma and, more rarely, other variants of focal production. These forms are potentially curable by adrenalectomy. Bilateral forms account for a substantial proportion of cases and are treated mainly through mineralocorticoid receptor antagonism, because removal of a single gland does not eliminate aldosterone excess.

A second classification is genetic and includes familial forms. These conditions are rare in the general population but become relevant when onset is early, severity is marked or familial clustering is evident. In some forms, aldosterone secretion may display distinctive characteristics and respond to additional therapeutic strategies beyond standard approaches. In others, the principal implication is recognition of familial risk and the need for structured specialist assessment.

From a phenotypic perspective, primary hyperaldosteronism may be divided into presentations with hypokalemia and normokalemic presentations. This distinction does not correspond directly to the severity of target-organ damage because excessive mineralocorticoid activation may occur even when potassium is normal. When present, hypokalemia tends to indicate more marked aldosterone excess or a context that promotes potassium loss, such as high sodium intake or diuretic therapy. It increases the risk of arrhythmias and neuromuscular symptoms but is not required to establish the indication for targeted treatment.

A practical criterion of severity is the degree of cardiovascular and renal involvement. The presence of atrial fibrillation, heart failure, significant left ventricular hypertrophy, previous stroke or albuminuria suggests a biologically more active or longer-standing disorder in which rapid and sustained reduction of mineralocorticoid activation becomes a priority. In these patients, determination of unilateral disease has greater prognostic value because surgical cure, when feasible, may reduce aldosterone exposure more effectively than medical therapy that has not been adequately titrated.

Classification should also include the quality of response to treatment. During medical therapy, an important pathophysiological objective is to achieve sufficiently effective mineralocorticoid receptor antagonism to correct potassium and blood pressure and attenuate renin suppression. Persistent renin suppression during treatment may indicate incomplete receptor blockade and ongoing risk. After surgery, response is assessed through a combination of biochemical and clinical outcomes because normalization of aldosterone physiology may occur even when hypertension does not resolve completely, particularly after years of disease with established vascular remodeling.

Treatment of primary hyperaldosteronism has two complementary objectives: controlling arterial blood pressure and reducing the systemic effects of excessive aldosterone-mediated activation of the mineralocorticoid receptor. Treatment selection depends on the lateralization of production, patient safety and the probability of long-term benefit. In general, unilateral forms are considered for surgery, while bilateral forms require chronic targeted medical therapy. The therapeutic approach should aim not only at the blood pressure target, but also at correction of the abnormal mineralocorticoid environment.

In unilateral forms, laparoscopic adrenalectomy is the treatment of choice when the patient is suitable and lateralization has been established with a high degree of reliability. Surgery removes the main source of aldosterone and frequently produces rapid biochemical normalization, improvement of hypokalemia and a reduction in the need for antihypertensive medications. The effect on blood pressure varies. Some patients achieve normotension without treatment, while others improve but remain hypertensive because of pre-existing vascular remodeling or other components of hypertension. This variability does not diminish the value of surgery because its most specific benefit is removal of aldosterone excess and consequent reduction of chronic mineralocorticoid activation.

Preoperative preparation is crucial for reducing perioperative risk. Correction of hypokalemia and adequate blood pressure control stabilize the patient and reduce cardiovascular complications. In many cases, temporary use of mineralocorticoid receptor antagonists or other antihypertensive treatments is useful for achieving clinical stability before surgery, especially in patients with arrhythmias or heart failure. Management must be individualized according to renal function, the risk of hyperkalemia and comorbidities.

In bilateral forms, or when surgery is not feasible or is declined, the cornerstone of treatment is therapy with mineralocorticoid receptor antagonists. Spironolactone and eplerenone reduce the renal and cardiovascular effects of aldosterone, correct hypokalemia and improve blood pressure control. Selection between them depends on tolerability, comorbidities and adverse-effect profiles. Spironolactone may cause antiandrogenic effects, whereas eplerenone is more selective but often requires higher doses or more frequent administration. When these treatments are not tolerated, or when the main objective is correction of hypokalemia through blockade of the sodium channel in the collecting duct, amiloride may be considered as an alternative or adjunct while preserving the therapeutic rationale of reducing the final effect of aldosterone on ion transport.

Medical therapy must be actively titrated. Simply adding spironolactone is insufficient if renin remains profoundly suppressed and blood pressure and potassium do not stabilize, because mineralocorticoid activation may remain clinically relevant. A pathophysiological approach aims to reduce mineralocorticoid signaling sufficiently to permit recovery of the renin-angiotensin system, in addition to controlling blood pressure and potassium, while respecting renal safety and the risk of hyperkalemia. This requires close follow-up during dose titration and systematic attention to renal function, potassium and pharmacological interactions.

Familial forms require specialist management. In selected conditions, additional treatments may be useful according to the underlying mechanism, but the objective remains the stable reduction of mineralocorticoid receptor exposure and blood pressure control. Management during pregnancy is particularly complex. Treatment selection must consider fetal and maternal safety, and the strategy should be coordinated through an integrated endocrinological and obstetric pathway, with careful balance between blood pressure control and electrolyte risk.

Specific treatment should be accompanied by measures addressing sodium intake because high sodium consumption amplifies the effects of aldosterone on volume and blood pressure. Reducing excess salt intake improves the response to mineralocorticoid receptor antagonists and decreases the hemodynamic burden. This does not replace causal or receptor-directed therapy, but enhances its effectiveness and reduces the need for pharmacological intensification that might increase adverse effects.

Follow-up in primary hyperaldosteronism is an active process aimed at confirming correction of mineralocorticoid signaling, maintaining stable blood pressure control and preventing complications, particularly hyperkalemia and declining renal function in patients receiving mineralocorticoid receptor antagonists. Assessments are more frequent during the initial phase, when medications are being titrated or during the perioperative period, and may be spaced out once stability has been achieved, provided that clear objectives and a reassessment plan have been established.

After adrenalectomy, monitoring includes blood pressure, potassium and renal function, with the expectation that correction of aldosterone excess will normalize electrolyte balance and improve the cardiovascular profile. In some patients, a period of reduced residual aldosterone production or relative hypoaldosteronism may occur, with a tendency toward hyperkalemia, particularly after prolonged suppression of the contralateral gland or in the presence of chronic kidney disease and advanced age. This risk requires close monitoring during the following weeks and cautious management of treatments that increase potassium.

During medical therapy, laboratory follow-up is based on potassium, creatinine and estimated glomerular filtration rate, together with functional assessment of treatment response. Blood pressure is a fundamental objective, but it is not the only one. Recovery of renin, when observed, suggests more effective reduction of mineralocorticoid activation. Conversely, persistent profound renin suppression, especially when associated with the need for multiple treatments and signs of target-organ damage, may indicate that therapy is not sufficiently attenuating aldosterone signaling. This should prompt reassessment of dose titration and adherence while maintaining an appropriate balance between safety and efficacy.

Cardiovascular surveillance is central. In patients with atrial fibrillation or a high arrhythmic risk, rhythm or rate management and assessment of thromboembolic risk must proceed in parallel with endocrine stabilization. Some arrhythmias may persist even after correction of aldosterone excess, especially when atrial remodeling is advanced. Nevertheless, reducing mineralocorticoid stimulation is essential for decreasing recurrence and progression.

From a renal perspective, monitoring albuminuria in addition to glomerular filtration is useful. A reduction in albuminuria after specific treatment is a favorable indicator of reduced aldosterone-mediated glomerular injury. Changes in filtration must be interpreted cautiously. Correction of hyperfiltration may lower estimated glomerular filtration rate without representing true deterioration. In such cases, the long-term trajectory and the course of albuminuria are often more informative than a single measurement.

Follow-up should also include patient education regarding recognition of electrolyte disturbances, management of sodium intake, awareness of treatments that increase potassium, and the need for additional assessments during dehydration, infections or changes in therapy. Patients who understand the rationale of mineralocorticoid-directed treatment and monitoring are more likely to adhere to therapy and less likely to experience preventable adverse events, particularly during treatment adjustment.

The prognosis of primary hyperaldosteronism improves substantially when diagnosis is timely and treatment is directed at the source of aldosterone excess or the mineralocorticoid receptor. The key point is that aldosterone excess confers a greater cardiovascular and renal risk than comparable essential hypertension. Correction of aldosterone signaling is therefore not merely a means of lowering blood pressure, but an intervention that reduces the likelihood of events such as atrial fibrillation, stroke and progression of nephropathy. The speed and completeness of recovery depend on the duration of exposure, the presence of established target-organ damage and the effectiveness of surgical or medical correction.

Cardiovascular complications are the most important prognostic concern. Primary hyperaldosteronism is associated with a higher frequency of atrial fibrillation and an increased risk of heart failure and stroke compared with essential hypertension. Correction of unilateral disease through adrenalectomy may markedly reduce the arrhythmogenic and profibrotic effects of aldosterone. During medical therapy, prognostic effectiveness depends on achieving sufficiently strong mineralocorticoid receptor antagonism. If blood pressure is controlled but renin remains suppressed and potassium remains unstable, part of the risk may persist because the mineralocorticoid receptor continues to receive a biologically relevant signal.

Renal complications include albuminuria, long-term decline in renal function and a risk profile that may initially be concealed by hyperfiltration. After specific treatment, glomerular filtration may decrease because of hemodynamic normalization. When this occurs together with reduced albuminuria and clinical stability, it is often compatible with a favorable renal effect. Over time, effective control of aldosterone signaling tends to reduce the progression of renal damage compared with nonspecific management.

Electrolyte complications have immediate clinical relevance. Hypokalemia may promote arrhythmias, weakness and neuromuscular complications, while hyperkalemia is a potential complication of treatment, particularly with mineralocorticoid receptor antagonists and in patients with impaired renal function or receiving other treatments that increase potassium. Prevention of hyperkalemia requires cautious titration, close monitoring and management of potassium intake and pharmacological interactions.

Treatment-related complications depend on the selected strategy. Surgery involves perioperative risks and the possibility of postoperative electrolyte abnormalities, including a period of relative hypoaldosteronism. Mineralocorticoid receptor antagonist therapy may be limited by adverse effects and the need for continuous monitoring. In a well-structured clinical pathway, these complications are largely preventable or manageable and should not delay correction of aldosterone excess, because the cumulative damage caused by untreated disease is often greater.

Overall, primary hyperaldosteronism has major prognostic relevance precisely because it is a cause of hypertension and target-organ damage that is potentially reversible or substantially modifiable. Prognosis is better when recognition occurs early and treatment is targeted and pathophysiologically effective, supported by follow-up that ensures electrolyte stability, blood pressure control and sustained reduction of mineralocorticoid activation.